Stock Taper
SCREENER COMPARE ANY 2 STOCKS
NPCE
NEUROPACE, INC.
NASDAQ
$14.03
▲ UP 0.07% (0.01)

KEY STATISTICS

Market Cap$478.34 M
52w High$19.60
52w Low$8.61
Dividend Yield—
Frequency—
P/E-24.61
Volume115.98K
Shares Out.34.09M

COMPANY

LEADERSHIP

Joel D. Becker
CHIEF EXECUTIVE
Joel D. Becker

COMPENSATION 2026

Salary$567,567
Stock Awards$587,340
Incentive Plan Pay$551,810
All Other Comp.$0
Total$2,408,566

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 22, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
220

PRICE TARGET

Target High$22.00
Target Low$20.00
Target Median$21.00
Target Consensus$21.00

UPCOMING EARNINGS

DateNov 3, 2026
DayTuesday
Rev. Est.$27.09M
NOV
3
TUE

PRICE

$14.03 ▲ UP 0.07% (+$0.01)
$13.90$14.00$14.10$14.209:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM14.03

About NeuroPace, Inc.

https://www.neuropace.com ↗

NeuroPace, Inc. develops and sells the RNS system, a brain-responsive neuromodulation device for treating refractory focal epilepsy, enabling personalized real-time treatment, remote monitoring, and data recording for hospital use.

INDUSTRY

Medical - Devices

A PRODUCT NEUROPACE, INC. IS KNOWN FOR

RNS System
RNS System

The RNS System is the first implantable, brain-responsive neurostimulation device that monitors and delivers personalized, real-time treatment for focal onset seizures in drug-resistant epilepsy patients.

COMPETITORS

COMPETITOR
ABT COMPARE
BSX COMPARE
LIVN COMPARE
MDT COMPARE
NMTC COMPARE

Revenue by Geography

MapREGIONQ2-2025Q4-2025Q1-2026Q2-2026
NonUS$400K $400K $700K ▲$400K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
63
LISTED HERE
10
RANKED BY POSITION SIZE
VTI
0.00% · 908.5K
XWEH.DE
0.07% · 741.2K
IWM
0.01% · 678.0K
ZPRR.DE
0.01% · 51.6K
GSSC
0.03% · 22.1K
RSSL
0.01% · 12.6K
SYZ
0.14% · 6.5K
URTY
0.00% · 1.1K
FSEG
0.09% · 447
SC0K.DE
0.01% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
71.09%
HOLDERS
152
TOP 12 OF 152 · RANKED BY POSITION SIZE
Polar Capital Holdings Plc
3.3M sh · $43.37M
Soleus Capital Management, L.P.
3.0M sh · $30.5M
First Light Asset Management, LLC
2.9M sh · $45.46M
Morgan Stanley
2.7M sh · $42.18M
Orbimed Advisors LLC
2.6M sh · $26.95M
Blackrock, Inc.
2.5M sh · $39.37M
Driehaus Capital Management LLC
1.5M sh · $23.33M
Vanguard Group Inc
1.5M sh · $22.89M
Armistice Capital, LLC
1.3M sh · $13.38M
Kent Lake Capital LLC
1.1M sh · $8.65M
Kent Lake Pr LLC
1.0M sh · $10.31M
Deutsche Bank AG\
938.9K sh · $14.92M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF MEDICAL OFFICER
Morrell Martha
Sale · 335 shares
2026-06-24
★
DIRECTOR
Kumar Rakhi
Purchase · 989 shares
2026-06-19
★
DIRECTOR
Geiger Uri
Purchase · 789 shares
2026-06-19
★
DIRECTOR
Fischer Frank M
Purchase · 1.5K shares
2026-06-19

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
OVERWEIGHT 2
4 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY UBS BUY JP Morgan OVERWEIGHT Wells Fargo OVERWEIGHT

SECTORS PEERS

PEERPRICE
DCTH$17.14COMPARE
BWAY$14.74COMPARE
CERS$2.81COMPARE
SGHT$8.26COMPARE
MASS$10.68COMPARE
SENS$9.71COMPARE
RXST$6.25COMPARE
GNLX$2.72COMPARE